Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) ...
14 Avril 2016 - 2:00PM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced that new data
from a pharmacokinetic modeling study designed to identify the dose
of cerdulatinib for expansion cohorts in a Phase 2 study will be
presented in a poster session at the American Association for
Cancer Research (AACR) Annual Meeting 2016, which is taking place
from April 16-20 in New Orleans.
Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in
development to treat patients with resistant or relapsed
hematologic cancer. Cerdulatinib inhibits two key cell signaling
pathways that promote cancer cell growth in certain hematologic
malignancies. Portola is evaluating cerdulatinib in an ongoing
Phase 1/2 study in patients with relapsed/refractory B-cell
malignancies who have failed multiple therapies.
The abstract will be made available at www.AACR.org.
Poster Presentation Details
- Abstract Title (#CT144): Preclinical and clinical studies and
modeling and simulation to identify Phase 2 dose for cerdulatinib:
a dual SYK/JAK inhibitor for the treatment of B-cell
malignancies
- Presenting Author: Janet M. Leeds, Ph.D., Senior Director, Drug
Metabolism and Pharmacokinetics, Portola Pharmaceuticals
- Poster Session Title: Phase I Clinical Trials 2
- Presentation Date and Time: Wednesday, April 20, 7:30 a.m. – 11
a.m. Central Time
- Location: Ernest N. Morial Convention Center, Halls G-J, Poster
Section 13
About Portola Pharmaceuticals, Inc. Portola
Pharmaceuticals is a biopharmaceutical company developing product
candidates that could significantly advance the fields of
thrombosis and other hematologic diseases. The Company is advancing
three programs, including betrixaban, an oral, once-daily Factor Xa
inhibitor; andexanet alfa, a recombinant protein designed to
reverse the anticoagulant effect in patients treated with an oral
or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK
inhibitor in development to treat hematologic cancers. Portola's
partnered program is focused on developing selective Syk inhibitors
for inflammatory conditions. For more information, visit
www.portola.com and follow the Company on Twitter
@Portola_Pharma.
Investor Contact:
Ana Kapor
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur